tbuckley/cabot-search huggingface dataset:
IgA bullous pemphigoid: a distinct blistering disorder.
Authors: R. RUSSELL JONES, S. K. GOOLAMALI
Journal: British Journal of Dermatology (1980)

We report a patient with an eccrine carcinoma who developed localized blistering which clinically resembled pemphigoid, histologically showed subepidermal blistering with features of both dermatitis herpetiformis and bullous pemphigoid, responded to dapsone and exhibited linear IgA deposition on direct immunofluorescence. The nosological position of patients with linear IgA deposition and subepidermal blistering is not clear. A review of the literature reveals that in adults linear IgA deposition may occur in three separate situations: dermatitis herpetiformis, bullous pemphigoid and a third condition of which our case is an example which is best termed IgA bullous pemphigoid. This condition is distinguished from cases of dermatitis herpetiformis with linear IgA by the clinical features and the site of IgA deposition on immunoelectronmicroscopy. It is distinguished from cases of bullous pemphigoid with linear IgA by the absence of circulating IgG antibasement membrane zone antibody, the therapeutic response to dapsone and the frequent occurrence of circulating IgA antibasement membrane zone antibody. IgA bullous pemphigoid has not previously been reported with a carcinoma but the association lends further support to the concept that this eruption represents a variant of pemphigoid.
PRIMARY AMYLOIDOSIS: REPORT OF A CASE
Authors: F E ZEMP
Journal: Annals of Internal Medicine (1947)

Case Reports1 March 1947PRIMARY AMYLOIDOSIS: REPORT OF A CASEF. EUGENE ZEMP, M.D., F.A.C.P.F. EUGENE ZEMP, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-26-3-448 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOnly in recent years has there been some unanimity of opinion in regard to the classification of amyloid disease which is divided into primary amyloidosis, secondary amyloidosis, amyloid associated with multiple myelomata and tumor-like formation.Primary amyloidosis is subdivided into the systemic and localized types in which some variation occurs. It was first described in 1856 by Wilks,1but is still poorly understood, and of unknown etiology. In 1936 Kerwin2reported two cases and in 1939 Koletsky and Stecher3made a comprehensive review of the literature noting some 30 cases, 22 of which were of the systemic type. They also...Bibliography1. WILKS S: Cases of lardaceous disease and some allied affections, Guy's Hosp. Rep., 1856, ii, 105. Google Scholar2. KERWIN AJ: Idiopathic amyloid disease of the heart, Jr. Lab. and Clin. Med., 1936, xxii, 255. Google Scholar3. KOLETSKYSTECHER SRM: Primary systemic amyloidosis, Arch. Path., 1939, xxvii, 267-288. Google Scholar4. LARSEN RM: Primary myocardial amyloidosis, Am. Jr. Path., 1930, vi, 147-160. Google Scholar5. BUDD JW: Primary amyloid disease of the heart, Am. Jr. Path., 1934, x, 299. Google Scholar6. BINFORD CH: Primary amyloid disease of the myocardium and blood vessels, Arch. Path., 1940, xxix, 314-320. Google Scholar7. SAPPINGTONDAVIEHORNEFF SWFHJ: Primary amyloidosis of the lungs, Jr. Lab. and Clin. Med., 1942, xxvii, 882-889. Google Scholar8. PEARSONRICEDICKENS BMMKL: Primary systemic amyloidosis, Arch. Path., 1941, xxxii, 1-10. Google Scholar9. DILLONEVANS JALR: Primary amyloidosis: A report of three cases, Ann. Int. Med., 1942 xvii, 722-730. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Columbia, South Carolina*Received for publication October 1, 1945. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Paramyloidose 1 March 1947Volume 26, Issue 3Page: 448-453KeywordsAmyloidosisEtiology ePublished: 1 December 2008 Issue Published: 1 March 1947 PDF downloadLoading ...
Abstract 11639: Interpretation of Diastolic Function in Hemodialysis Patients: The Importance of a Load Independent Index of Left Ventricular Diastolic Compliance
Authors: Ruth F Dubin, Dean Alokozai, Sanjiv J Shah
Journal: Circulation (2014)

Background: Prior studies of diastolic function in the setting of end-stage renal disease (ESRD) primarily utilize E/e’, a volume dependent measure of left ventricular (LV) filling pressure. While such studies show that high E/e’ is common and associated with adverse outcomes in ESRD, these findings may not be attributable to intrinsic diastolic function. In contrast to E/e’, the LV end-diastolic pressure-volume relationship (EDPVR) (a load independent index of LV diastolic compliance) describes intrinsic LV diastolic function. Therefore, we sought to examine the effects of hemodialysis on EDPVR, and to delineate correlates of EDPVR in the setting of ESRD. We hypothesized that E/e’ and other indices of diastolic function are volume dependent in ESRD, while EDPVR is not. Methods: Twenty-nine patients underwent echocardiography directly before and during the last hour of dialysis. LV diastolic compliance was quantified using a single-beat EDPVR method (P = αVβ). The LV end-diastolic volume at an idealized pressure of 20 mmHg (EDV20) was calculated as a means of comparing EDPVR curves within and between patients (smaller EDV20 = lower diastolic compliance). Results: During hemodialysis, EDV20 did not significantly change (median [IQR] pre-dialysis EDV20 112 [93-113] ml; intra-dialysis EDV20 113 [94-138] ml; p=0.2). However, E/e’ decreased on average by 1.2 absolute units (AU) (median [IQR] pre-dialysis 7.0 [6.0-8.9] AU; intra-dialysis 6.0 [5.1-9.7] AU; p=0.004). E/e’ decreased by 2 AU for every 1 L/hr ultrafiltration rate (p=0.07). Significant correlates of lower pre-dialysis EDV20 (stiffer LV) included higher diastolic blood pressure (DBP) (β=-13 ml EDV20 per 10 mmHg DBP, p=0.005) and concentric LV remodeling, (β=-5ml EDV20 per 0.1 g/ml LV mass/volume ratio, p=0.004). NT-proBNP was associated with higher E/e’, (β=0.2 E/e’ per 1000 pg/ml higher NT-proBNP, p&lt;0.001), but was not a significant correlate of EDV20 (p=0.5). Conclusions: LV end-diastolic compliance (EDV20) is less volume dependent than LV filling pressures (E/e’) in the setting of ESRD, and thus may be a better measure of intrinsic diastolic function than E/e’. Further studies are needed to determine whether EDV20 predicts adverse outcomes in the ESRD population.
Pancreatic Cystadenomata
Authors: Charles E. Piper
Journal: JAMA (1962)

Cystic lesions of the pancreas are uncommon, and of these, benign cystadenomata are less than 10 per cent. Review of the literature reveals approximately 100 verified cases. The files of the Mayo Clinic provided 20 cases of benign cystadenomata for study. Analysis of this group of cases reveals that this is primarily a disease of middle-aged women. Symptoms are those of a slowly expanding lesion with general discomfort from pressure and occasional pain aggravated by bending or motion. A palpable mass is a significant finding. Usually, it is in the upper abdomen to the left of the midline. The efficacy of complete excision is emphasized. This method gave a successful result in all 14 cases in which it was used. Marsupialization and drainage must be avoided because 3 of 4 lesions so treated recurred.
Effects of tumor-like assay conditions, ionizing radiation, and hyperthermia on immune lysis of tumor cells by cytotoxic t-lymphocytes.
Authors: John W. Harris
Journal: Cancer Research (1976)

Cytotoxic T-lymphocytes (CTL's) harvested from mixed splenic lymphocyte cultures (DBA/2 + C57BL) were tested for their ability to lyse allogeneic P815 mastocytoma cells under various tumor-like assay conditions, with or without previous exposure to ionizing radiation or hyperthermia (43°). There was little or no decrease of immune cytolysis when CTL's were assayed by 51Cr release under tumor-like conditions (plateau-phase target cells, low pH, or anoxia) or after irradiation, but cytolytic activity was greatly reduced when CTL's were exposed to heat; 45 min of hyperthermic treatment decreased activity by ≥99% while reducing the apparent cell viability (as indicated by trypan blue exclusion) by only 30%. When the P815 target cells rather than the CTL's were exposed to heat, their susceptibility to immune lysis was not affected even after treatment times that were lethal to the tumor cells. Despite the dissimilar heat sensitivities of CTL and P815 cells, the dose-response curves for inhibition of protein synthesis by heat, as indicated by [3H]leucine incorporation, were similar for both cell types; neither the depression of protein synthesis in heated CTL's nor the decreased cytolytic ability of these cells was reversed within 3 hr. When irradiated or heated P815 cells were incubated with CTL's, the resulting survival curves were always additive, indicating that neither irradiation nor heat treatment affected the susceptibility of the tumor cells to immune attack. The extreme heat sensitivity of cytotoxic T-lymphocytes raises important questions about the possible effects of hyperthermic treatment on the immune competence of cancer patients.
Catalonia plans new policy on frozen embryos
Authors: Xavier Bosch, Joaquim Pérez-Martinez
Journal: BMJ (1998)

When embryos are frozen as part of infertility treatment the couple should either agree to donate any “spare” ones so that other women can adopt them or only a small number of eggs will be extracted for fertilisation, according to legislation planned in Catalonia, Spain.

The legislation has yet to be finally approved by the Catalonian parliament. But in the meantime the health department will …
Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population
Authors: Lori B. Daniels, Gail A. Laughlin, Mark J. Sarno, Ricki Bettencourt, Robert L. Wolfert, Elizabeth Barrett-Connor
Journal: Journal of the American College of Cardiology (2008)
Ketoconazole in the Management of Fungal Disease.
Authors: H M Sinclair
Journal: Annals of Internal Medicine (1981)

This book is beautifully produced and is a pleasure to read.Ketoconazole is a major advance in the treatment of the mycoses.The first one-third of the book reviews the superficial and deep mycoses and their current treatment.All this information is available elsewhere, but it is well brought together and is a good 'back-drop' for the rest of the book which is devoted to the pharmacology and clinical experience with Ketoconazole.Ketoconazole is an exciting new drug and this excitement is evident in the book.It is emphasized how useful it is in some of the deep mycoses.For the dermatologist it has transformed the management of chronic mucocutaneous candidiasis.In the chapter on 'Ketoconazole in Perspective' I was disappointed that it was not recommended to keep the drug as a special one for defined clinical entities.Ketoconazole will rarely be required for dermatophyte infections when Griseofulvin is such a useful and well tolerated drug, or where topical treatment alone will suffice.Ketoconazole will rarely be required for cutaneous candida infections, where topical treatment will usually cure.It seems to be totally unjustified for the manufacturers to list pityriasis versicolor as an indication for its use, when this trivial infection can be treated with topical agents.The photographs are mostly good and some are excellent, but a few are grossly overexposed.In conclusion, a useful book and should be read by all clinicians who treat fungal infections.It is a pity that the authors have not given a stronger lead into when this drug is indicated.
Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families
Authors: Chang-Fu Kuo, Matthew J. Grainge, Ana M. Valdes, Lai-Chu See, Shue-Fen Luo, Kuang-Hui Yu, Weiya Zhang, Michael Doherty
Journal: JAMA Internal Medicine (2015)

IMPORTANCERelatives of patients with systemic lupus erythematosus (SLE) appear to be at higher risk of SLE and other autoimmune diseases, but estimates of individual familial risks are largely unavailable or unreliable.Furthermore, relative contributions of genetic, shared, and unshared environmental factors to SLE susceptibility remain unclear.OBJECTIVE To examine familial aggregation and heritability of SLE and the relative risks (RRs) of other autoimmune diseases in relatives of patients with SLE. DESIGN, SETTING, AND PARTICIPANTSA population-based family study using the Taiwan National Health Insurance Research Database was conducted.Participants included all individuals (N = 23 658 577) registered with that database in 2010; of these, 18 283 had SLE.We identified 21 009 551 parent-child relationships, 17 168 340 full sibling pairs, and 342 066 twin pairs.Diagnoses of SLE were ascertained from March 1, 1995, to December 31, 2010, and analysis was conducted between March 1 and August 15, 2014. MAIN OUTCOMES AND MEASURESThe prevalence and RRs of SLE and other autoimmune diseases in relatives and spouses of patients with SLE as well as the relative contributions of heritability, shared, and nonshared environmental factors to SLE susceptibility.RESULTS Among the more than 23 million participants, the RRs (95% CIs) for SLE were 315.94 (210.66-473.82)for twins of the patients, 23.68 (20.13-27.84)for siblings, 11.44 (9.74-13.43)for parents, 14.42 (12.45-16.70)for offspring, and 4.44 (2.38-8.30)for spouses without genetic similarity.The accountability for phenotypic variance of SLE was 43.9% for heritability, 25.8% for shared environmental factors, and 30.3% for nonshared environmental factors.The RRs (95% CIs) in individuals with a first-degree relative with SLE were 5.87 (4.89-7.05)for primary Sjögren syndrome, 5.40 (3.37-8.65)for systemic sclerosis, 2.95 (2.04-4.26)for myasthenia gravis, 2.77 (1.45-5.32)for idiopathic inflammatory myositis, 2.66 (2.28-3.11)for rheumatoid arthritis, 2.58 (1.16-5.72)for multiple sclerosis, 1.68 (1.22-2.32)for type 1 diabetes mellitus, 1.39 (0.66-2.91) for inflammatory bowel diseases, and 0.86 (0.43-1.71) for vasculitis. CONCLUSIONS AND RELEVANCEThe individual risks of SLE and other autoimmune diseases were increased in families that included patients with SLE.The heritability of SLE was estimated to be 43.9%.These data should be considered when counseling families with affected members.
Abstract 4235: Anti-proliferative effect of (19<i>Z</i>)-halichondramide from the sponge <i>Chondrosia corticata</i> via G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells
Authors: Song Y. Bae, Jayoung Song, Yoonho Shin, Won Kyung Kim, Jedo Oh, Tae Joon Choi, Eun Ju Jeong, So Hyun Park, Eun Jeong Jang, Ji In Kang, Hyen Joo Park, Ji-Young Hong, Gi Dae Kim, Ju-eun Jeon, Jongheon Shin, Sang Kook Lee
Journal: Cancer Research (2014)

Abstract Five oxazole-containing macrolides isolated from the marine sponge Chondrosia corticata were evaluated for their anti-proliferative activity in a panel of human solid cancer cell lines. (19Z)-Halichondramide ((19Z)-HCA), a novel trisoxazole-containing macrolide, exhibited the highest potency among the macrolides, with IC50 values in the submicro-molar ranges. Prompted by the high potency of growth inhibition of cancer cells, we investigated the mechanism of action of the anti-proliferative activity of (19Z)-HCA in human A549 lung cancer cells. (19Z)-HCA induced cell cycle arrest in the G2/M phase, and this event was highly correlated with the expression of checkpoint proteins, including the up-regulation of p53 and GADD45α and the down-regulation of cyclin B1, cyclin A, CDC2, and CDC25C. In addition, the growth inhibition by (19Z)-HCA was associated with the suppression of mTOR and its downstream effector molecules 4EBP1 and p70S6K. The modulation of mTOR signaling by (19Z)-HCA was found to be mediated by the regulation of upstream proteins, including the down-regulation of Akt and p38 MAPK and the up-regulation of AMPK. These data suggest the potential of (19Z)-HCA to serve as a candidate for cancer chemotherapeutic agents derived from marine organisms by virtue of arresting the cell cycle in the G2/M phase and the modulation of mTOR/AMPK signaling pathways. [Acknowledgements: This work was supported by the MarineBio Research Program (NRF-2013045101) of the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MEST).] Citation Format: Song Yi Bae, Jayoung Song, Yoonho Shin, Won Kyung Kim, Jedo Oh, Tae Joon Choi, Eun Ju Jeong, So Hyun Park, Eun Jeong Jang, Ji In Kang, Hyen Joo Park, Ji-Young Hong, Gi Dae Kim, Ju-eun Jeon, Jongheon Shin, Sang Kook Lee. Anti-proliferative effect of (19Z)-halichondramide from the sponge Chondrosia corticata via G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4235. doi:10.1158/1538-7445.AM2014-4235
Metabolism of N -2-Fluorenylacetamide in X/Gf Mice: Lack of Correlation Between Biochemical Interaction and Carcinogenicity
Authors: Preston H. Grantham, Letitia C. Mohan, Elizabeth K. Weisburger
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Metabolism of N-2-Fluorenylacetamide in X/Gf Mice: Lack of Correlation Between Biochemical Interaction and Carcinogenicity Get access Preston H. Grantham, Preston H. Grantham Search for other works by this author on: Oxford Academic PubMed Google Scholar Letitia C. Mohan, Letitia C. Mohan Search for other works by this author on: Oxford Academic PubMed Google Scholar Elizabeth K. Weisburger Elizabeth K. Weisburger 2We are indebted to Dr. Anna Goldfeder, City of New York Department of Health and Hospitals, who supplied the X/Gf mice. The technical assistance of Anna Parker, and the secretarial assistance of Frances M. Williams are also gratefully acknowledged 3Steroid suspending vehicle contains polysorbate 80 (0.4%), carboxymethyl cellulose (0.5%), and benzyl alcohol (0.9%) in 0.9% NaCl solution. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 3, March 1976, Pages 649–651, https://doi.org/10.1093/jnci/56.3.649 Published: 01 March 1976 Article history Received: 27 June 1975 Accepted: 17 October 1975 Published: 01 March 1976
The JAMA 1998 Editorial Peer Review Audit
Authors: Elaine S. Williams
Journal: JAMA (1999)

Elaine S. Williams WE HEREBY THANK THE 3555 PEER REVIEWERS WHO completed JAMA manuscript reviews in 1998 and whose names appear on the following pages. In 1998, it took an average of 43 calendar days from manuscript receipt to rejection; 120 days from receipt to acceptance; and 180 days from receipt to publication. The total acceptance rate for manuscripts in 1998 was 15%, and the acceptance rate for unsolicited manuscripts was 9%.
ABDOMINAL MANIFESTATIONS OF RHEUMATIC FEVER: DESCRIPTION OF A RIGHT RECTUS SYNDROME
Authors: Norman Reitman
Journal: Annals of Internal Medicine (1945)

Article1 May 1945ABDOMINAL MANIFESTATIONS OF RHEUMATIC FEVER: DESCRIPTION OF A RIGHT RECTUS SYNDROMENORMAN REITMAN, M.D.NORMAN REITMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-22-5-671 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe abdominal manifestations of rheumatic fever have been known since Andral, in 1839, called attention to the presence of abdominal pain in cases showing other evidences of rheumatic fever. The French, who were the first to study this problem, found signs and symptoms of peritoneal irritation in rheumatic fever, manifested chiefly by attacks of abdominal pain at the onset of rheumatic activity, and found that when the arthritic pains began the abdominal pains stopped and vice versa.This important association of abdominal pain and rheumatic fever has largely escaped the attention of the internist and the surgeon. Poynton,1in 1925,...Bibliography1. POYNTON FJ: Osler's Modern Medicine (McCrea), Third Edition, 1925, Lea & Febiger, Philadelphia, ii, 187. Google Scholar2. GRAHAMPAUL RSJR: Studies in rheumatic fever: I. A brief review of clinical and gross pathological findings in eighteen fatal cases, Bull. Ayre Clinical Laboratory, 1926, x, 44. Google Scholar3. WOODELIASON FCEC: Rheumatic peritonitis, Am. Jr. Med. Sci., 1931, clxxxi, 482-494. CrossrefGoogle Scholar4. GEPTILL P: Differential diagnosis of abdominal manifestations of acute rheumatic fever from acute appendicitis, Ann. Surg., 1934, xcix, 650-660. CrossrefGoogle Scholar5. BABBAGEMCLAUGHLINFRUIN DECWIL: Strain of right rectus muscle simulating acute appendicitis, War Med., 1944, v, 280-283. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New Brunswick, New Jersey*Received for publication July 26, 1944.This work was done before the author entered the Military Service. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byErkrankungen des EndokardRHEUMATIC NEPHRITIS*HAROLD F. ROBERTSON, M.D., F.A.C.P., SAMUEL T. SCHLAMOWITZ, M.D. 1 May 1945Volume 22, Issue 5Page: 671-678KeywordsAbdominal painArmed forcesPainRheumatic feverRheumatic painSigns and symptomsSurgeons ePublished: 1 December 2008 Issue Published: 1 May 1945 PDF downloadLoading ...
Cost-effectiveness of Ximelagatran for Stroke Prevention
Authors: Christine Perret-Guillaume, Denis Wahl
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 9389: Pre- Diabetes and the Risk of Incident Diabetes Mellitus and Cardiovascular Events in an Adult Population. MESA
Authors: Joseph Yeboah, David M Herrington, Alian Bertoni, Wendy Post, Gregory L Burke
Journal: Circulation (2010)

Background: Hyperglycemia is a well-established cardiovascular risk factor; however, the association between impaired fasting glucose (IFG) (100 – 125mg/dl) and cardiovascular disease (CVD) is less...
Abstract 3463: Incidence, Clinical Findings and Outcome of White Women with Left Ventricular Apical Ballooning Syndrome
Authors: Guido Parodi, Stefano Del Pace, Nazario Carrabba, Claudia Salvadori, Gentian Memisha, Ignazio Simonetti, David Antoniucci, Gian Franco Gensini
Journal: Circulation (2006)

Background: Left ventricular apical ballooning syndrome (LVABS) is a clinical condition, that may mimic ST-elevation acute myocardial infarction. Objective: To assess the incidence, clinical findin...